Publication Results

Generate Report

Add publications by marking their checkboxes, or

Targeting cholecystokinin-2 receptor for pancreatic cancer chemoprevention.

Mohammed A,  Janakiram NB,  Suen C,  Stratton N,  Lightfoot S,  Singh A,  Pathuri G,  Ritchie R,  Madka V,  Rao CV
Mol Carcinog 2019 Oct;58(10):1908-1918
Major Program(s) or Research Group(s): Chemopreventive Agent DevelopmentProstate and Urologic Cancer
PubMed ID: 31313401
PMC ID: PMC6721979 [available on October 01, 2020]

Lack of chemopreventive effects of P2X7R inhibitors against pancreatic cancer.

Mohammed A,  Janakiram NB,  Madka V,  Pathuri G,  Li Q,  Ritchie R,  Biddick L,  Kutche H,  Zhang Y,  Singh A,  Gali H,  Lightfoot S,  Steele VE,  Suen CS,  Rao CV
Oncotarget 2017 Nov 17;8(58):97822-97834
Major Program(s) or Research Group(s): Chemopreventive Agent DevelopmentProstate and Urologic Cancer
PubMed ID: 29228654
PMC ID: PMC5716694

Safety and Preclinical Efficacy of Aerosol Pioglitazone on Lung Adenoma Prevention in A/J Mice.

Seabloom DE,  Galbraith AR,  Haynes AM,  Antonides JD,  Wuertz BR,  Miller WA,  Miller KA,  Steele VE,  Suen CS,  O'Sullivan MG,  Ondrey FG
Cancer Prev Res (Phila) 2017 Feb;10(2):124-132
Major Program(s) or Research Group(s): Chemopreventive Agent DevelopmentProstate and Urologic Cancer
PubMed ID: 27993834
PMC ID: PMC5687250

Raloxifene hydrochloride for breast cancer risk reduction in postmenopausal women.

Provinciali N,  Suen C,  Dunn BK,  DeCensi A
Expert Rev Clin Pharmacol 2016 Oct;9(10):1263-1272
Major Program(s) or Research Group(s): BiometryProstate and Urologic Cancer
PubMed ID: 27583816
PMC ID: not available

Celecoxib Alters the Intestinal Microbiota and Metabolome in Association with Reducing Polyp Burden.

Montrose DC,  Zhou XK,  McNally EM,  Sue E,  Yantiss RK,  Gross SS,  Leve ND,  Karoly ED,  Suen CS,  Ling L,  Benezra R,  Pamer EG,  Dannenberg AJ
Cancer Prev Res (Phila) 2016 Sep;9(9):721-31
Major Program(s) or Research Group(s): Prostate and Urologic Cancer
PubMed ID: 27432344
PMC ID: PMC5010963

The National Cancer Institute's PREVENT Cancer Preclinical Drug Development Program: overview, current projects, animal models, agent development strategies, and molecular targets.

Shoemaker RH,  Suen CS,  Holmes CA,  Fay JR,  Steele VE
Semin Oncol 2016 Feb;43(1):189-197
Major Program(s) or Research Group(s): Chemopreventive Agent DevelopmentProstate and Urologic Cancer
PubMed ID: 26970137
PMC ID: PMC4789768

Effect of ED-71, an analogue of Vitamin D3, on intestinal neoplasia in the Apc plus /Min-FCCC mouse model

Chang Wen-Chi L.,  Kaunga Esther,  Cooper Harry S.,  Vanderveer Lisa,  Peng Jing,  Zhang Yongchao,  Suen Chen S.,  Clapper Margie L.
Cancer Res 2015 Aug 1;75(Suppl 15):Abstract 2806
Major Program(s) or Research Group(s): Chemopreventive Agent Development
PubMed ID: not available
PMC ID: not available

Omeprazole alone, or in combination with Aspirin inhibits azoxymethane-induced colon adenoma progression to adenocarcinoma and carcinoma invasion in F344 rat model

Mohammed Altaf,  Patlolla Jagan M. R.,  Zhang Yuting,  Biddick Laura,  Madka Venkateshwar,  Li Qian,  Lightfoot Stan,  Lubel Ronald,  Suen Chen S.,  Steele Vernon E.,  Rao Chinthalapally V.
Cancer Res 2015 Aug 1;75(Suppl 15):Abstract 2820
Major Program(s) or Research Group(s): Chemopreventive Agent DevelopmentProstate and Urologic Cancer
PubMed ID: not available
PMC ID: not available